rawpixel / iStockphoto.com
Thomas Kirkbak, chief IP litigation specialist at Danish company Lundbeck, faces challenges on several fronts, as he explains to LSIPR.
IP infringement covering pharmaceuticals typically takes place where generic companies can make the most profits, according to Thomas Kirkbak, chief IP litigation specialist and attorney-at-law at Lundbeck.
“If a lot of money can be made by entering a generic product on a certain market, my experience is that the generic companies are willing to take substantial risks of infringing the originator’s IP rights,” he says.
Kirkbak explains that a generic will usually first infringe in the US, because that is where the biggest profits can be made. This is followed by challenges to the IP rights in the UK and Germany.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
LSIPR 50 2017, Thomas Kirkbak, Lundbeck, IP litigation, generic product, generics, pharmaceutical, damages, infringement,